← Back to Home

A New Option After Chemotherapy and Immunotherapy: sac-TMT Extends Survival in Advanced Endometrial Cancer

In a 776-patient phase 3 trial, sac-TMT extended median overall survival from 12.1 months to 19 months, but grade 3 or higher treatment-related adverse events were also more frequent. The FDA has accepted the application for priority review. Translating efficacy into clinical treatment choices still requires consideration of toxicity and evidence across different patient populations.

By SURL BioNews

When platinum-based chemotherapy and immunotherapy both fail to stop endometrial cancer from progressing, subsequent treatment options are often limited. Results from the phase 3 TroFuse-005 trial announced on October 26 provide new evidence to address this challenge: compared with chemotherapy, the antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) both delayed disease progression and extended overall survival. However, the higher rate of severe side effects remains an essential consideration when evaluating this therapy.

The randomized, open-label trial, funded by Merck/MSD, enrolled 776 patients with advanced or recurrent endometrial cancer who had previously received platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. According to NYU Langone Health, which participated in the study, enrollment spanned 29 countries and more than 200 cancer centers; 386 patients received sac-TMT, and 390 received physician’s choice of doxorubicin or paclitaxel chemotherapy. The results were presented at the European Society for Medical Oncology Congress and simultaneously published in The Lancet.

At a median follow-up of 14 months, median overall survival was 19.0 months in the sac-TMT group and 12.1 months in the chemotherapy group; the hazard ratio for death was 0.68, corresponding to a 32% reduction in the relative risk of death during follow-up. Median progression-free survival increased from 3.9 months to 7.2 months, with a 41% reduction in the relative risk of disease progression or death. Reuters also independently reported these two primary findings. These population-level differences do not mean that every patient will live longer by the same amount of time.

Developed by Kelun-Biotech and advanced in collaboration with Merck, sac-TMT uses an antibody to recognize the TROP2 protein on the surface of tumor cells, then delivers a drug that inhibits topoisomerase I, disrupting cancer cell survival. In the trial, the objective tumor response rate was 35.1%, compared with 17.3% in the chemotherapy group; among patients who responded, median response duration was 11.1 months and 6.9 months, respectively. This adds evidence of tumor control alongside the survival data.

The trade-off was treatment toxicity. Grade 3 or higher treatment-related adverse events occurred in 54.4% of the sac-TMT group and 41.4% of the chemotherapy group; common problems included anemia, neutropenia, and oral mucositis. Treatment discontinuation due to treatment-related adverse events occurred in 3.1% and 4.9%, respectively, and each group had 3 treatment-related deaths. OncLive reported that the incidence and severity of stomatitis declined after the trial protocol was amended to add prophylactic steroid mouthwash, but this before-and-after comparison must still be interpreted separately from the primary efficacy results from the randomized groups.

The success of the overall trial also does not mean that the same benefit has been established across all tumor types. According to exploratory analyses summarized by OncLive, the overall survival hazard ratio was 0.62 in patients with proficient DNA mismatch repair (pMMR), compared with 0.99 in patients with deficient DNA mismatch repair (dMMR), with a 95% confidence interval of 0.60 to 1.63. The researchers cautioned that the small subgroup had limited patient numbers and a wide range of estimates, and that no formal interaction analysis had been performed. These findings therefore cannot establish that the treatment is ineffective in dMMR patients or directly serve as rules for treatment selection.

The U.S. Food and Drug Administration (FDA) has accepted the marketing application for sac-TMT for adults with endometrial cancer who have previously received platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor, granting priority review with a target decision date of June 15, 2027. Priority review does not yet mean approval. The current evidence supports a survival advantage over two chemotherapy options in this previously treated patient population; whether that benefit can extend to earlier treatment settings remains a question for other trials.

References

  1. Merck
  2. NYU Langone Health
  3. OncLive
  4. Reuters (via 710 AM WDSM)